Bay Area biotech hauls in $62M to pay the freight on ear­ly-stage CD33/CD3 T cell en­gager

South San Fran­cis­co-based Am­phive­na Ther­a­peu­tics has hauled in $62 mil­lion in cash as the R&D team slogs through ear­ly-stage de­vel­op­ment of their bis­pe­cif­ic CD33 and CD3 T cell en­gager.

CEO Jean­marie Guenot says that their bis­pe­cif­ic “se­lec­tive­ly elim­i­nates myeloid-de­rived sup­pres­sor cells (MD­SC) in can­cer pa­tients while spar­ing nor­mal neu­trophils and mono­cytes.” The drug was in-li­censed from Af­fimed, which had some clin­i­cal trou­ble with their own in-house ap­proach to CD19/CD3, which was put on hold by the FDA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.